Blood Glucose

Diabetes devices such as sensors, insulin pumps and continuous glucose monitors continue to improve, offering people with diabetes more opportunities for connected care. As a result, adoption of these technologies is gradually rising. Approximately 30% to 40% of people with type 1 diabetes and an increasing number of people with insulin-dependent type 2 diabetes are using pump and sensor technology, according to a 2018 review published in Diabetes Care. Another recent study shows CGM can be cost-effective for adults with diabetes when compared with the daily use of test strips and improves overall blood glucose levels while reducing hypoglycemia.

Among a cohort of adults with type 2 diabetes, HbA1c and fasting plasma glucose were effectively reduced via treatment with the small-molecule glucagon receptor antagonist RVT-1502, according to findings published in Diabetes Care.

Children and adolescents with type 1 diabetes assigned insulin glargine injection 300 U/mL for 26 weeks experienced a reduction in HbA1c similar to that of children assigned insulin glargine 100 U/mL, according to findings from the randomized phase 3b EDITION JUNIOR study presented at International Society for Pediatric and Adolescent Diabetes Annual Meeting.

In group medical visits for diabetes, adding intensive weight management with low-carbohydrate diets was as effective in improving blood sugar levels as conventional medication management, according to study results published in JAMA Internal Medicine.

When assessing glycemic management in diabetes, measuring glycated albumin may be a more effective tool than measuring HbA1c, particularly among patients with a recent diabetes diagnosis, according to findings published in the Journal of Diabetes and its Complications.

It is a sad fact that – even as prevalent as kidney disease has become in the United States – many Americans have no idea that, albeit silently, their kidney function is deteriorating. As we know, there are often few obvious, outward signs. Genetics and race play a role; but whereas people might be aware that their blood pressure is high, they could stand to lose some weight or that their blood sugars are elevated, not enough individuals know to connect the dots between these medical issues and the functional longevity of their kidneys.

Abbott and Sanofi on Monday announced a partnership to develop new tools that will combine technology from Abbott’s FreeStyle Libre continuous glucose monitor with insulin dosing information for future Sanofi smart pens, insulin titration apps and cloud software, according to a press release from the companies.

PARIS — Patients with CHD and diabetes who received frequent educational and motivational text messages for glycemic control in addition to standard care had a greater reduction in glycated hemoglobin than those who received standard care, according to the results of the CHAT-DM study.

A cohort of individuals with diabetes who used a continuous glucose monitor with predictive low-glucose suspend insulin delivery technology spent less time with blood glucose below 70 mg/dL and experienced fewer hypoglycemic episodes than when they were not using the system, according to findings published in Diabetes Technology & Therapeutics.

Among a cohort of patients with type 2 diabetes who decided not to take insulin, the odds of achieving lower HbA1c measures were eight times higher for those who made adjustments to their lifestyle practices compared with those who did not, according to findings published in the Journal of Diabetes and its Complications.